Table 1.
Clinical and histopathological characteristics of HER2-positive and TNBC cases with neoadjuvant chemotherapy (NAC) in the study cohort and external validation cohort.
| Cohort | Characteristics | Study cohort | External validation cohort | |||
|---|---|---|---|---|---|---|
| Case #/median | %/Range | Case #/median | %/Range | |||
| HER2+ | Total case number | 62 | – | 20 | – | |
| Cases with residual tumor | 24 | 38.71% | 10 | 50.00% | ||
| Cases with pCR | 38 | 61.29% | 10 | 50.00% | ||
| Age (years) | 56 | 30–76 | 43 | 30–69 | ||
| Nottingham grade | I | 1 | 1.61% | 0 | 0.00% | |
| II | 27 | 43.55% | 2 | 10.00% | ||
| III | 34 | 54.84% | 18 | 90.00% | ||
| Nuclear grade | I | 0 | 0.00% | 0 | 0.00% | |
| II | 10 | 16.13% | 1 | 5.00% | ||
| III | 52 | 83.87% | 19 | 95.00% | ||
| Estrogen receptor (ER) positive | 30 | 48.39% | 13 | 65.00% | ||
| Progesterone receptor (PR) positive | 19 | 30.65% | 10 | 50.00% | ||
| HER2/CEP17 ratio | 6.73 | 1.23–22.98 | 7.00 | 0.96–11.10 | ||
| Residual cancer burden, if applicable | 1.39 | 0.91–4.14 | 1.98 | 0.98–4.67 | ||
| TNBC | Total case number | 64 | – | 20 | – | |
| Cases with residual tumor | 37 | 57.81% | 10 | 50.00% | ||
| Cases with pCR | 27 | 42.19% | 10 | 50.00% | ||
| Age (years) | 51 | 26–74% | 57 | 32–79% | ||
| Nottingham grade | I | 0 | 0% | 1 | 5.00% | |
| II | 15 | 23.4% | 3 | 15.00% | ||
| III | 49 | 76.6% | 16 | 80.00% | ||
| Nuclear grade | I | 0 | 0% | 1 | 5.00% | |
| II | 9 | 14.1% | 2 | 10.00% | ||
| III | 55 | 85.9% | 17 | 85.00% | ||
| Residual cancer burden, if applicable | 2.01 | 0.80–4.27 | 2.14 | 0.77–3.61 | ||
For complete study cohort metadata, please refer to Supplementary Information.